Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637
Alebund Pharmaceuticals (Jiangsu) Limited Class H financial statements
Alebund Pharmaceuticals (Jiangsu) Limited Class H's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 30.6M | 6.53M |
| Cost of revenue | 17.1M | 4.14M |
| Gross profit | 13.4M | 2.38M |
| Research and development | 372.6M | 235.4M |
| Selling, general and administrative | 52.1M | 17.2M |
| Operating income | -641.3M | -306.9M |
| Depreciation and amortization | 44.7M | 12.5M |
| EBITDA | -596.5M | -294.4M |
| Interest expense | 110.5M | 29.4M |
| Income before tax | -751.8M | -335.1M |
| Net income | -750.0M | -326.0M |
| Earnings per share, basic | -2.21 | -0.96 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 358.3M | 343.8M |
| Short-term investments | 172.8M | 22.3M |
| Receivables | 0 | 865.0K |
| Inventory | 10.3M | 6.12M |
| Current assets | 558.7M | 388.8M |
| Total assets | 1.34B | 1.11B |
| Accounts payable | 67.8M | 25.9M |
| Current liabilities | 239.8M | 1.94B |
| Long-term debt | 545.3M | 445.3M |
| Total liabilities | 836.7M | 2.45B |
| Shareholders' equity | 503.2M | -1.33B |
| Shares outstanding | 339.9M | 339.9M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -287.9M | -249.9M |
| Capital spending | -101.6M | -236.7M |
| Free cash flow | -389.5M | -486.6M |
| Change in cash | 17.0M | 280.4M |